Chancery Division.

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement In ’09 2009 the Patents Court of the High Court, Chancery Division, made the decision that Occlutech’s selection of Figulla ASD and PFO occluders do not infringe the U.K dmae.review . Component of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal in London announced its decision confirming having said that Figulla ASD and PFO occluders do not infringe said patent. AGA asked for authorization to appeal to the Supreme Courtroom , but that program was refused. It really is now open to AGA to make an application immediate to the Supreme Court for permission to charm, but permission sparingly is granted just, such as in instances that involve a point of law of public importance.

CeTeCancer and ADI collaborate for research study Radient Pharmaceuticals Corporation , a US-based pharmaceutical company, declared today it has entered right into a collaboration contract through its wholly owned subsidiary AMDL Diagnostics, Inc. The objective of the study project is to identify an effective early-detection and prevention program for lung tumor. CeTeCancer will provide medical samples and perform all clinical testing. The research project is supported by INNOVA CORFO and can run for 18 months with final results expected to be published in early 2011. Related StoriesNew results reveal association between colorectal cancer and melanoma drug treatmentMeat-rich diet may increase kidney cancers riskNew RNA check of blood platelets can be used to detect location of tumor We are delighted to enter this partnership with an extremely innovative scientific group working to detect and possibly avoid the deadly and world-wide spread of lung cancer, stated Mr.